Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

As new therapies designed to cut off sickle cell disease pathology at the root advance through the clinic, the field is moving beyond endpoints centered on pain crises to readouts based on hemoglobin. A single,...

Amgen to accelerate China strategy via BeiGene deal

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...

AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation. As...

Vertex’s triple therapy will reshape the landscape of cystic fibrosis trials

FDA approval of Vertex’s long-awaited triple therapy for cystic fibrosis is likely to seal the company’s dominance in the indication for years to come, with competitive threats barely touching the horizon. Moreover, uptake of the...

Novartis, Merck KGaA see opportunity in select pockets of MS patients

As companies continue to pile into the multiple sclerosis market with new therapies, Novartis and Merck KGaA are dissecting the landscape to define populations for their newly launched drugs. While the former is staking out...

Amgen deal gives BeiGene dry powder to grow its own pipeline

In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed...

How a KRAS program transformed Mirati's story

With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied...

If approved, aducanumab will still have hills to climb

As doctors digest Biogen’s aducanumab data, the possible approval of the first disease-modifying therapy for Alzheimer’s disease is raising questions around reimbursement and how to build the necessary infrastructure among physicians and hospitals. While investors...

Deciding factors in the shifting MS treatment landscape

The efficacy and convenience advantages that established oral medicines as the go-to therapy in multiple sclerosis are the same factors now squeezing them out. Two years post-launch, the success of injectable Ocrevus ocrelizumab from Roche...

Biogen’s aducanumab pleases investors, confounds doctors

Biogen has only upside in the short term following its turnaround decision to push aducanumab down the regulatory path for Alzheimer’s disease. But physicians’ split responses to the apparently contradictory data could presage longer-term regulatory...

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...

Relmada data offer hope of safer option for depression

Relmada more than doubled its share price Tuesday after reporting Phase II data hinting that REL-1017 could be as effective at treating depression as J&J’s Spravato without the psychotomimetic side effects that require physician monitoring....

UCB adding Ra’s rare immunology assets in $2.5B takeout

UCB is looking to build its rare disease immunology franchise through its proposed $2.5 billion acquisition of Ra Pharmaceuticals -- a price that more than doubles the biotech’s valuation. The deal would give UCB S.A....

Lessons from Healey ALS on how to build platform trials quickly

The first ever platform trial in ALS provides a recipe for getting these collaborative studies off the ground quickly and with early buy-in from companies. Platform trials take advantage of a master protocol to test...